Forty Seven 2

Forty Seven, Inc. was a clinical-stage immuno-oncology biopharmaceutical company developing therapies that target cancer immune-evasion pathways, based on technology licensed from Stanford University. Its lead program, magrolimab, was a monoclonal antibody against the CD47 "don't eat me" signal, evaluated in myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. Seeded by Lightspeed Venture Partners in 2015, the company completed an IPO in 2018 and was acquired by Gilead Sciences in 2020 for approximately $4.9 billion, becoming a wholly-owned Gilead subsidiary. As a therapeutics developer it exposes no public developer platform, API, or SDK surface; its former site (fortyseveninc.com) now redirects to gilead.com.

Forty Seven 2 is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Immuno-Oncology, Healthcare, and Clinical Stage.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-09-08 · rubric v0.20.0

0 APIs

Company Biopharmaceutical Immuno-Oncology Healthcare Clinical Stage Acquired Life Sciences

Kin Score

Kin Score How this is scored →
scored 2026-09-08 · rubric v0.20.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Well-Known Document 0 / 5

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero: never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and several others — scorable at all.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/forty-seven-2: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Resources

Company 2

The organization behind the API

Website

Website

CrunchBase

CrunchBase

Other 1

Properties that don't map to a standard resource type

ParentCompany

ParentCompany

Source (apis.yml)

aid: forty-seven-2
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/forty-seven-2.png
name: Forty Seven 2
description: Forty Seven, Inc. was a clinical-stage immuno-oncology biopharmaceutical company developing therapies that target
  cancer immune-evasion pathways, based on technology licensed from Stanford University. Its lead program, magrolimab, was
  a monoclonal antibody against the CD47 "don't eat me" signal, evaluated in myelodysplastic syndrome, acute myeloid leukemia,
  non-Hodgkin lymphoma, and solid tumors. Seeded by Lightspeed Venture Partners in 2015, the company completed an IPO in 2018
  and was acquired by Gilead Sciences in 2020 for approximately $4.9 billion, becoming a wholly-owned Gilead subsidiary. As
  a therapeutics developer it exposes no public developer platform, API, or SDK surface; its former site (fortyseveninc.com)
  now redirects to gilead.com.
url: https://raw.githubusercontent.com/api-evangelist/forty-seven-2/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lightspeed-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-status-note: Acquired by Gilead Sciences in 2020 (~$4.9B); biopharma therapeutics developer with no public API/developer
  surface. The "2" suffix is a portfolio-scraper dedup artifact.
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Immuno-Oncology
- Healthcare
- Clinical Stage
- Acquired
- Life Sciences
tags_raw:
- Company
- Biopharmaceutical
- Immuno-Oncology
- Healthcare
- Clinical-Stage
- Acquired
- Life Sciences
apis: []
common:
- type: ParentCompany
  url: https://apis.io/providers/gilead-sciences/
  name: Gilead Sciences
  x-relationship: acquired
  x-evidence: Seeded by Lightspeed Venture Partners in 2015, the company completed an IPO in 2018 and was acquired by Gilead
    Sciences in 2020 for approximately $4.
- type: Website
  url: https://www.gilead.com/
- type: CrunchBase
  url: https://www.crunchbase.com/organization/forty-seven-inc
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools →

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/forty-seven-2"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/forty-seven-2/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/forty-seven-2/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.